On pins and needles: Will COVID-19 vaccines ‘save the world’
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
As the novel coronavirus continues to spread and the pursuit of a vaccine intensifies, debate has grown — Will we have a COVID-19 vaccine? If so, when? And how much value can it provide to society?

Here is what we found:

• Early data on vaccine safety and immunogenicity in Phase I and II trials are promising—although in a limited number of subjects to date.

• More than 50 candidates are expected to enter human trials in 2020, and 250 total vaccine candidates are being pursued.

• Historical attrition rates would suggest that such a pipeline could yield more than seven approved products over the next few years.

• Hurdles: Validating unproven platform technologies, demonstrating vaccine candidates’ safety and protection, and delivering highest-impact vaccine profiles.

• Regulatory bodies are still finalizing guidelines for COVID-19 vaccines. Recent guidance from the US FDA, for example, suggests the need for more data prior to granting Emergency Use Authorizations (EUAs).

• Vaccine manufacturers have announced cumulative capacity that could produce as many as one billion doses by the end of 2020 and nine billion doses by the end of 2021.

Taken together, all the evidence suggests that COVID-19 vaccines are likely to become available for focused populations somewhere between the fourth quarter of 2020 and the first quarter of 2021.

Source: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/on-pins-and-needles-will-covid-19-vaccines-save-the-world#
P●●●a S●●h and 14 others like this4 shares